title: Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma.
abstract: Antitumour activity of cytotoxic agents, evaluated in patients with AIDS-related Kaposi's sarcoma (KS), is about 30-80%. However, responses are mostly partial and short. Experience with etoposide is similar. Teniposide has a longer elimination half-life and superior antitumour activity compared with etoposide in some experimental models. Thus a phase II trial was done in 25 patients with AIDS-related KS. Teniposide was given by 60-min infusion at 360 mg/m2 every 3 weeks. 10 (40%) showed a partial response, median duration of 9 (6-20) weeks. The main side-effects were leukopenia, thrombocytopenia, nausea and vomiting, alopecia and mucositis.
authors.affiliation: AIDS and Oncology Unit, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil.
authors.forename: G
authors.initials: G
authors.lastname: Schwartsmann
authors.forename: E
authors.initials: E
authors.lastname: Sprinz
authors.forename: M
authors.initials: M
authors.lastname: Kronfeld
authors.forename: J
authors.initials: J
authors.lastname: Vinholes
authors.forename: E
authors.initials: E
authors.lastname: Sander
authors.forename: M
authors.initials: M
authors.lastname: Zampese
authors.forename: R
authors.initials: R
authors.lastname: Preger
authors.forename: L
authors.initials: L
authors.lastname: Kalakun
authors.forename: A L
authors.initials: AL
authors.lastname: Brunetto
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000505:Alopecia / Q000139:chemically induced; D004341:Drug Evaluation; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D009325:Nausea / Q000139:chemically induced; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology; D013713:Teniposide / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors
chemical_list: D013713:Teniposide